|1.||Cosenzi, Alessandro: 2 articles (01/2003 - 04/2002)|
|2.||Rabasseda, X: 1 article (12/2006)|
|3.||Prous, J R: 1 article (12/2006)|
|4.||Bayes, M: 1 article (12/2006)|
|5.||Prasad, S K: 1 article (06/2006)|
|6.||Smith, G C: 1 article (06/2006)|
|7.||Barlow, M M: 1 article (06/2006)|
|8.||Grothues, F: 1 article (06/2006)|
|9.||Dargie, H J: 1 article (06/2006)|
|10.||Cleland, J G F: 1 article (06/2006)|
06/09/1998 - "With the use of serial MRI and histologic measurements, it is demonstrated that protection from both lumen volume reduction and neointima formation is obtained in this model by use of a potent, nonpeptide dual ET(A)/ET(B) receptor antagonist, SB 217242. "
06/09/1998 - "Application of serial in vivo magnetic resonance imaging to evaluate the efficacy of endothelin receptor antagonist SB 217242 in the rat carotid artery model of neointima formation."
11/01/1999 - "Ten minutes before hypoxemia, the Hyp group (n = 10) was given saline and the 1-mg (n = 9) and 5-mg group (n = 9), respectively, were given 1 and 5 mg/kg i.v. SB 217242 (an ET receptor antagonist). "
01/01/1999 - "SB 217242 (3.6 or 10.8 mg/day, ip) markedly reduced (80 and 95%, respectively) hypoxia-induced increases in pulmonary artery pressure. "
01/01/1999 - "There was no difference in the sensitivity to ET-1 or the potency of SB 217242 in pulmonary artery from normoxic rats vs. rats exposed to hypoxia (9% O2) for 14 days. "
01/01/1999 - "Effect of SB 217242 on hypoxia-induced cardiopulmonary changes in the high altitude-sensitive rat."
12/01/1997 - "SB 217242, administered by continuous intraperitoneal infusion via mini osmotic pump (0.36, 3.6 or 10.8 mg/day), significantly reduced (by about 50%) hypoxia-induced pulmonary artery pressure increases at all three doses used. "
|3.||Pulmonary Hypertension (Ayerza Syndrome)
12/01/1997 - "The results of the present study provide further preclinical evidence for a pathophysiological role of ET-1 and the potential therapeutic utility of ET receptor antagonists, such as SB 217242, in pulmonary hypertension."
01/01/1999 - "The inhibitory effects of SB 217242 on the functional and remodeling changes induced by hypoxia provide further evidence that ET may play a central role in pulmonary hypertension and that ET receptor antagonists may have a utility in the treatment of this disease."
01/01/1998 - "The inhibitory influence of SB 217242 on the functional and morphologic changes induced by hypoxia provides further evidence for a role for ET and the potential utility of ET receptor antagonists in the treatment of pulmonary hypertension."
12/01/1997 - "This study investigated the effects of the nonpeptide endothelin (ET) receptor antagonist, SB 217242, against ET-1-induced pulmonary pressor responses and in a model of hypoxia-induced pulmonary hypertension in the guinea pig. "
01/01/1995 - "The fact that a 30% reduction in ischemic brain injury can be demonstrated after oral administration of SB 217242 suggests that ET antagonists may be of therapeutic utility in focal stroke."
10/01/2001 - "In the current study, the effects of an orally active mixed endothelin-A/endothelin-B (ETA /ETB ) receptor antagonist (enrasentan) were assessed in a model of cardiac hypertrophy and dysfunction (spontaneously hypertensive stroke prone rats) maintained on a high-salt/high-fat diet. "
|5.||Hypertension (High Blood Pressure)
04/01/2002 - "The aim of this study was to evaluate whether enrasentan could reverse the hypertension and reduce the target organ damage induced by an HFD. "
01/01/2003 - "In rats with hyperinsulinemia and hypertension enrasentan normalized blood pressure and prevented cardiac and renal damage. "
04/01/2002 - "Antihypertensive treatment with enrasentan (SB217242) in an animal model of hypertension and hyperinsulinemia."
|1.||Endothelin Receptors (Endothelin Receptor)
|4.||Measles-Mumps-Rubella Vaccine (MMR Vaccine)
|5.||Yellow Fever Vaccine (Vaccine, Yellow Fever)
|7.||Succinic Acid (Succinate)
|9.||Interleukin-12 (IL 12)